// App-Quantinova.ai

1611 : Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study

Researchers

Presenter

  • Esther Natalie Oliva

Principal Investigators

  • Uwe Platzbecker

  • Guillermo Garcia-Manero

  • Ghulam J. Mufti

  • Valeria Santini

  • Mikkael A. Sekeres

  • Rami S. Komrokji

  • Jeevan K. Shetty

  • Derek Tang

  • Shien Guo

  • Weiqin Liao

  • George Zhang

  • Xianwei Ha

  • Rodrigo Ito

  • Jennifer Lord-Bessen

  • Jay T. Backstrom

  • Pierre Fenaux

Medical Centers

  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

  • Dept. Hematology and Cell Therapy,University Hospital Leipzig,Leipzig,Germania

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

  • Cleveland Clinic Foundation, Cleveland, OH

  • Moffitt Cancer Center, Tampa, FL

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Evidera, Waltham, MA

  • Acceleron Pharma, Cambridge, MA

  • Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7,Paris,France

Locations

  • Italy

  • Germany

  • United States

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

  • Solid malignancies

Biomarkers

  • Solute Carrier Family 12 Member 2

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • luspatercept

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02631070

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved